It called for releasing information about how much a drug is likely to cost consumers as well as the true cost of developing that drug — including how much the government spent on research — before a new treatment receives approval from the Food and Drug Administration. The FDA currently can't take into consideration the expected price of drugs or even whether they are better than competitors currently on the market, Doherty said.